Rituximab, cyclophosphamide, bortezomib and prednisone (R-CBorP): Final results of a phase I trial evaluating two dosing schedules and the safety of overlapping pegfilgrastim in patients with relapsed/refractory indolent and mantle cell lymphomas Meeting Abstract
| Authors: | Gerecitano, J.; Portlock, C. S.; Hamlin, P. A.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Schulman, P.; Dumitrescu, O.; Sarasohn, D.; Pappanicholaou, J.; Iassonos, A.; Zhang, Z.; Horanlli, E.; Rojas, C. N.; Zelenetz, A. D.; O'Connor, O. A. |
| Abstract Title: | Rituximab, cyclophosphamide, bortezomib and prednisone (R-CBorP): Final results of a phase I trial evaluating two dosing schedules and the safety of overlapping pegfilgrastim in patients with relapsed/refractory indolent and mantle cell lymphomas |
| Meeting Title: | 51st Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 114 |
| Issue: | 22 |
| Meeting Dates: | 2009 Dec 5-8 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2009-11-20 |
| Start Page: | 1428 |
| Language: | English |
| ACCESSION: | WOS:000272725804372 |
| PROVIDER: | wos |
| PUBMED: | 22276299 |
| DOI: | 10.1182/blood.V114.22.3708.3708 |
| Notes: | Meeting Abstract: 3708 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
